Repligen Corporation to Present at Upcoming Investor Conferences

Rhea-AI Summary

Repligen (NASDAQ:RGEN) has announced its participation in three major investor conferences in November 2024. The company will present at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 14, the Stifel Healthcare Conference in New York City on November 19, and the Stephens Annual Investment Conference in Nashville on November 20.

CFO Jason Garland and CEO Olivier Loeillot will participate in analyst-led discussions at these events. All presentations will be available via live webcast through Repligen's Investor Relations website, with -time replay access after the events.

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences.

• The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.
• The Stifel Healthcare Conference being held November 18-19 in New York City. Olivier Loeillot, Chief Executive Officer, and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Tuesday, November 19, at 12:40 p.m. ET.
• The Stephens Annual Investment Conference being held November 19-21 in Nashville. Olivier Loeillot, Chief Executive Officer, and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Wednesday, November 20, at 10:00 a.m. ET.

A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

FAQ

Which investor conferences will Repligen (RGEN) attend in November 2024?

Repligen will attend three conferences: the UBS Global Healthcare Conference (November 11-14), the Stifel Healthcare Conference (November 18-19), and the Stephens Annual Investment Conference (November 19-21).

When is Repligen's (RGEN) presentation at the UBS Global Healthcare Conference?

Repligen's CFO Jason Garland will present at the UBS Global Healthcare Conference on Thursday, November 14, 2024, at 10:15 a.m. ET.

How can investors access Repligen's (RGEN) conference presentations?

Investors can access live webcasts of the presentations through Repligen's Investor Relations website at www.repligen.com, with replay options available for a time after each event.

Who will represent Repligen (RGEN) at these investor conferences?

CEO Olivier Loeillot and CFO Jason Garland will represent Repligen at the Stifel and Stephens conferences, while CFO Jason Garland will present alone at the UBS conference.